Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Rating of “Moderate Buy” by Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $6.8750.

A number of equities research analysts recently weighed in on SRTS shares. Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Maxim Group lowered their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday, April 21st. Finally, Alliance Global Partners started coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They set a “buy” rating and a $7.50 price target for the company.

Sensus Healthcare Trading Up 0.5%

SRTS opened at $3.96 on Tuesday. The company has a fifty day simple moving average of $4.13 and a 200 day simple moving average of $4.13. The firm has a market cap of $65.18 million, a price-to-earnings ratio of -8.43 and a beta of 1.28. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The firm had revenue of $4.94 million for the quarter, compared to analyst estimates of $8.35 million. Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SRTS. Opes Wealth Management LLC acquired a new position in Sensus Healthcare during the 3rd quarter worth $50,000. XTX Topco Ltd acquired a new position in Sensus Healthcare during the 4th quarter worth $77,000. Jane Street Group LLC acquired a new position in Sensus Healthcare during the 4th quarter worth $79,000. Mindset Wealth Management LLC grew its holdings in Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC acquired a new position in Sensus Healthcare during the 4th quarter worth $219,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.